OBJECTIVES: The European Health Data and Evidence Network (EHDEN) is a federated network of real-world data from partners across Europe, standardised to the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM). We demonstrate how EHDEN can provide real world evidence (RWE) that can be used to inform selection of long-term overall survival extrapolations. Such extrapolations are used in economic evaluations for health technology assessment (HTA) to assess cost effectiveness over a lifetime.

METHODS: Observational data on overall survival for common cancers (e.g., breast, lung) and one rarer cancer (head and neck) was obtained from the UK Clinical Practice Research Datalink (CPRD) between 2000 and 2019. Parametric curves were fitted to extrapolate long-term survival. The corresponding graphs and goodness of statistical fit measures (AIC & BIC) were uploaded to a user-friendly interactive R shiny dashboard.

RESULTS: Results derived from CPRD patient level data have been successfully uploaded to our “Cancer Survival Dashboard”. CPRD data covers up to 14years of follow-up, which is a significantly longer follow up than clinical trial data submitted as part of companies’ health technology assessment which is often immature (1-2 years). Users of the dashboard will be able to select a database from a dropdown menu, and then explore the survival extrapolations of 8 different cancers with age and sex adjustments/stratifications. A study-a-thon is being planned in early 2024 to incorporate data from additional data partners across Europe.

CONCLUSIONS: Federated data networks like EHDEN can provide access to RWE which can benefit HTA. The survival dashboard developed for this use case provides results with a longer follow-up than trials. This extended follow-up can help reduce the uncertainty around which long-term extrapolations are most plausible. Additionally, in the case of single arm trials, such data could potentially be used to inform the comparator survival estimates.